Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Cascadian Therapeutics, Inc. | v59738e8vk.htm |
Exhibit 99.1
Oncothyreon Reports Second Quarter 2011 Financial Results
Company to Hold Conference Call at 4:30 p.m. EDT Today
SEATTLE, WASHINGTON — August 8, 2011 — Oncothyreon Inc. (NASDAQ: ONTY) today reported
financial results for the second quarter ending June 30, 2011.
Net loss from operations increased to $5.8 million in the second quarter of 2011 from $4.7 million
in the second quarter of 2010, and to $11.7 million for the six months ended June 30, 2011 compared
to $10.2 million for the comparable period in 2010. This increase in net loss from operations for
the three and six months ended June 30, 2011 compared to prior year periods was primarily the
result of increased research and development expenses offset in part by a decrease in general and
administrative expenses.
Research and development expenses increased to $4.2 million in the second quarter of 2011 from $2.9
million in the second quarter of 2010, and to $8.4 million for the first six months of 2011 from
$5.5 million for the first six months of 2010, reflecting increased development activity for
Oncothyreon’s product candidates PX-866 and ONT-10. General and administrative expenses decreased
to $1.6 million in the second quarter of 2011 from $1.9 million in the second quarter of 2010, and
to $3.5 million for the first six months of 2011 from $4.7 million for the first six months in
2010. The decrease in general and administrative expenses was primarily a result of lower legal and
consulting expenses relating to regulatory compliance.
Net loss for the three months ended June 30, 2011 was $34.0 million or $0.91 per basic and diluted
share, compared with a net loss of $4.3 million, or $0.17 per basic and diluted share, for the
comparable period in 2010. Oncothyreon also reported a net loss of $41.1 million, or $1.22 per
basic and diluted share, for the six months ended June 30, 2011, compared with a net loss of $5.1
million, or $0.20 per basic and diluted share, for the six months ended June 30, 2010. The increase
in net loss for the three and six months ended June 30, 2011 compared to the same periods in the
prior year was primarily attributable to the non-cash expense as a result of the change in fair
value of warrant liability of $28.4 million and $34.5 million, respectively, which was primarily
due to an increase in Oncothyreon’s stock price.
As of June 30, 2011, Oncothyreon’s cash, cash equivalents and short-term investments were $66.8
million, compared to $28.9 million as of December 31, 2010. The $37.9 increase is attributable to
the closing of an underwritten public offering completed on May 4, 2011 of 11,500,000 shares of
Oncothyreon common stock at a price to the public of $4.00 per share for gross proceeds of $46.0
million and to the $5.0 million in funding
from the initial term loan with General Electric Capital Corporation. The net proceeds from the
sale of the shares, after deducting the underwriters’ discounts and other estimated offering
expenses payable by Oncothyreon, were approximately $43.0 million. This increase was offset by
$9.9 million cash used in operations and capital expenditures during the six months ending June 30,
2011.
Financial Guidance
Oncothyreon believes the following financial guidance to be correct as of the date provided.
Oncothyreon is providing this guidance as a convenience to investors and assumes no obligation to
update it.
Expenses in 2011 are expected to be higher when compared to 2010, primarily as a result of the more
advanced clinical development of PX-866 and IND-enabling development activities for ONT-10.
Oncothyreon currently expects cash used in operations in 2011 to be approximately $23 million. As a
result, Oncothyreon estimates that its existing cash will be sufficient to fund operations for at
least the next 12 months.
Conference Call and Webcast
Oncothyreon will conduct a conference call to discuss its second quarter 2011 financial results and
provide a review of its pipeline of products in development today at 4:30 p.m. Eastern time (1:30
p.m. Pacific time). To participate in the call by telephone, please dial (877) 280-7291 (United
States) or (707) 287-9361 (International). In addition, the call will be webcast live and can be
accessed on the “Events” page of the “News & Events” section of Oncothyreon’s website at
www.oncothyreon.com. An archive of the webcast will be available after completion of the
discussion and will be posted on Oncothyreon’s website.
About Oncothyreon
Oncothyreon is a biotechnology company specializing in the development of innovative therapeutic
products for the treatment of cancer. Oncothyreon’s goal is to develop and commercialize novel
synthetic vaccines and targeted small molecules that have the potential to improve the lives and
outcomes of cancer patients. For more information, visit www.oncothyreon.com.
Forward-Looking Statements
In order to provide Oncothyreon’s investors with an understanding of our current results and future
prospects, this release may contain statements that are forward-looking. Any statements contained
in this press release that are not statements of historical fact may be deemed to be
forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “will,”
“intends,” “potential,” “possible” and similar expressions are intended to identify forward-looking
statements. These forward-looking statements include our expectations regarding future expenses,
clinical development activities and the use and adequacy of cash resources.
Forward-looking statements involve risks and uncertainties related to our business and the general
economic environment, many beyond our control. These risks, uncertainties
and other factors could cause our actual results to differ materially from those projected in
forward-looking statements, including the risks associated with the costs and expenses of
developing our product candidates, the adequacy of financing and cash reserves on hand, changes in
general accounting policies, general economic factors, achievement of the results we anticipate
from our clinical trials with our products and our ability to adequately obtain and protect our
intellectual property rights. Although we believe that the forward-looking statements contained
herein are reasonable, we can give no assurance that our expectations are correct. All
forward-looking statements are expressly qualified in their entirety by this cautionary statement.
For a detailed description of our risks and uncertainties, you are encouraged to review the
official corporate documents filed with the securities regulators in the United States on U.S.
EDGAR and in Canada on SEDAR. Oncothyreon does not undertake any obligation to publicly update its
forward-looking statements based on events or circumstances after the date hereof.
Additional Information
Additional information relating to Oncothyreon can be found on U.S. EDGAR at www.sec.gov and on
SEDAR at www.sedar.com.
Investor and Media Relations Contact:
Julie Rathbun
Rathbun Communications
206-769-9219
ir@oncothyreon.com
Julie Rathbun
Rathbun Communications
206-769-9219
ir@oncothyreon.com
ONCOTHYREON INC. 2601 Fourth Avenue, Suite 500, Seattle, WA 98121
Tel: (206) 801-2100 Fax: (206) 801-2101
http://www.oncothyreon.com
Tel: (206) 801-2100 Fax: (206) 801-2101
http://www.oncothyreon.com
Oncothyreon Inc.
Condensed Consolidated Statements of Operations Data
(in thousands except share and per share amounts)
(unaudited)
Condensed Consolidated Statements of Operations Data
(in thousands except share and per share amounts)
(unaudited)
| Three months ended | Six months ended | |||||||||||||||
| June 30, | June 30, | |||||||||||||||
| 2011 | 2010 | 2011 | 2010 | |||||||||||||
Revenue |
||||||||||||||||
Licensing revenue from
collaborative and licensing agreements |
$ | — | $ | 4 | $ | 145 | $ | 9 | ||||||||
Operating expenses |
||||||||||||||||
Research and development |
4,193 | 2,862 | 8,381 | 5,469 | ||||||||||||
General and administrative |
1,633 | 1,860 | 3,462 | 4,691 | ||||||||||||
Total operating expenses |
5,826 | 4,722 | 11,843 | 10,160 | ||||||||||||
Loss from operations |
(5,826 | ) | (4,718 | ) | (11,698 | ) | (10,151 | ) | ||||||||
Other income (expense) |
||||||||||||||||
Investment and other income, net |
51 | 12 | 364 | 52 | ||||||||||||
Interest expense |
(175 | ) | — | (274 | ) | — | ||||||||||
Change in fair value of warrant liability |
(28,023 | ) | 366 | (29,481 | ) | 4,987 | ||||||||||
Total other income (expense), net |
(28,147 | ) | 378 | (29,391 | ) | 5,039 | ||||||||||
Net loss |
$ | (33,973 | ) | $ | (4,340 | ) | $ | (41,089 | ) | $ | (5,112 | ) | ||||
Loss per share — Basic and diluted |
$ | (0.91 | ) | $ | (0.17 | ) | $ | (1.22 | ) | $ | (0.20 | ) | ||||
Shares used to compute basic and diluted
loss per share |
37,433,822 | 25,753,405 | 33,781,593 | 25,753,405 | ||||||||||||
Oncothyreon Inc.
Consolidated Balance sheet data
(in thousands except share amounts)
(unaudited)
Consolidated Balance sheet data
(in thousands except share amounts)
(unaudited)
| June 30, | December 31, | |||||||
| 2011 | 2010 | |||||||
Cash, cash equivalents and
short term investments |
$ | 66,832 | $ | 28,877 | ||||
Total assets |
$ | 71,799 | $ | 34,445 | ||||
Long term liabilities |
$ | 46,691 | $ | 13,727 | ||||
Stockholder’s equity |
$ | 21,652 | $ | 18,857 | ||||
Common shares outstanding |
41,641,393 | 30,088,628 | ||||||